Učitavanje...
Safety of tumor necrosis factor inhibitor use in patients with concomitant malignancy
BACKGROUND/AIMS: Safety for tumor necrosis factor inhibitors (TNFi) in cancer has been focused on risk of incident malignancies, but studies on prognostic effects have been scarce. We determined survival and recurrence rates at 1, 2, and 5 years after cancer diagnosis in patients with and without co...
Spremljeno u:
| Izdano u: | Intest Res |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Korean Association for the Study of Intestinal Diseases
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7385568/ https://ncbi.nlm.nih.gov/pubmed/32252501 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5217/ir.2019.09140 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|